Correspondence | Published:

Statins for primary prevention: identifying low-risk individuals

Nature Reviews Cardiology volume 10, page 547 (2013) | Download Citation

We read the Review by Željko Reiner (Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2013.80)1 with great interest. We are particularly interested in the role of statins in primary prevention of cardiovascular disease (CVD) in individuals at low cardiovascular risk.

As was well discussed in the Review, clear evidence exists to support the use of statins for primary prevention in high-risk individuals.1 A risk of developing CVD >20% over 10 years, or >10% over 5 years, is widely used as the cut-off point for prescribing statins.2 However, the use of statins in low-risk individuals is controversial. A meta-analysis from the Cholesterol Treatment Trialists' (CTT) Collaborators showed that statins reduce the risk of major cardiovascular events by about 20% across all levels of baseline risk (even in individuals with a 5-year risk of major vascular events that is <10%).3 The CTT Collaborators suggested that the current guidelines for CVD prevention might need to be reconsidered.3 Their study raises enthusiasm for statins in the primary prevention of CVD in individuals at low cardiovascular risk. In fact, some have advocated treating 'all comers' with statins.4 Several issues, however, should be considered before advocating the widespread use of statins in individuals at low risk, such as the feasibility, desirability, and cost-effectiveness of such a strategy, and the quality of life for apparently healthy individuals who are prescribed lifelong drug therapy. Also important are potential adverse effects of statins.2,5,6

We agree that statins are likely to be beneficial to patients with low cardiovascular risk calculated using traditional risk-assessment algorithms, such as the Framingham Risk Score and the SCORE (Systematic COronary Risk Estimation) charts.4 However, additional risk-stratification options are needed to guide the use of statins in low-risk individuals. Data from the JUPITER trial7 showed that individuals with an elevated level of C-reactive protein measured by the high-sensitivity assay (hs-CRP) benefit from statin use, regardless of their LDL-cholesterol level. After this trial, hs-CRP is becoming accepted as a novel cardiovascular risk factor.7

Coronary artery calcium (CAC) scoring has been shown to predict coronary events beyond the use of the traditional Framingham Risk Score, with a high CAC burden (≥300) being associated with increased risk.8,9 Data from comparative effectiveness studies have suggested that quantification of CAC is a superior method to measurement of the hs-CRP level for improving risk assessment.10 Investigators in the St. Francis Heart Study11 enrolled patients with an elevated CAC level (CAC >80th percentile) and randomly allocated them to receive 20 mg of atorvastatin daily or placebo. The overall result did not meet statistical significance (P = 0.08) because of the limited power of the trial, but showed that atorvastatin significantly reduced the composite rate of adverse events from coronary heart disease by 30%.11

In conclusion, the use of statins for primary prevention in low-risk individuals remains an ambiguous area. We believe that additional risk-stratification options (such as measurement of the hs-CRP level and CAC scoring) should be explored in this population. A new risk-assessment algorithm that includes the traditional risk measures, but also incorporates these novel markers should be developed to identify low-risk patients and guide the prophylactic use of statins.

References

  1. 1.

    Statins in the primary prevention of cardiovascular disease. Nat. Rev. Cardiol. .

  2. 2.

    & Improving vascular health: are pills the answer? BMJ 344, e3802 (2012).

  3. 3.

    et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581–590 (2012).

  4. 4.

    , , , & Cardiovascular disease prevention: matching evidence-based algorithms with individualized care. Clin. Pharmacol. Ther. 93, 321–323 (2013).

  5. 5.

    & Statins for all by the age of 50 years? Lancet 380, 545–547 (2012).

  6. 6.

    et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews Issue 1. Art. No.: CD004816. .

  7. 7.

    et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).

  8. 8.

    et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as “low risk” based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). Arch. Intern. Med. 167, 2437–2442 (2007).

  9. 9.

    et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 107, 2571–2576 (2003).

  10. 10.

    et al. Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study. Lancet 378, 684–692 (2011).

  11. 11.

    , , , & Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J. Am. Coll. Cardiol. 46, 166–172 (2005).

Download references

Acknowledgements

The authors of this manuscript are funded by the Medical Scientific Research Grant of the Health Ministry of Guangdong province, China (No. B2011310, No. A2012663), and Scientific Research Fund of Foshan, Guangdong, China (No. 201208210).

Author information

Affiliations

  1. Department of Cardiology, the Affiliated Hospital at Shunde (the First People's Hospital of Shunde), Southern Medical University, Penglai Road 1, Daliang Town, Shunde District, Foshan 528300, People's Republic of China

    • Yu-li Huang
    •  & Yan-xian Wu
  2.  The Second Clinical Medicine Institute, Guangdong Medical College, Dongguan, People's Republic of China

    • Yi Huang

Authors

  1. Search for Yu-li Huang in:

  2. Search for Yi Huang in:

  3. Search for Yan-xian Wu in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Yu-li Huang.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrcardio.2013.80-c1

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing